Aspen gets $115M for Parkinson’s cell therapy, potential IPO in sight next yearnews2025-11-20T12:02:48+00:00November 20th, 2025|Endpoints News|
Flagship’s Tessera to start first human trial using new gene writing platformnews2025-11-19T20:38:49+00:00November 19th, 2025|Endpoints News|
Protara trumpets small rare disease dataset in children for cell therapynews2025-11-19T15:57:02+00:00November 19th, 2025|Endpoints News|
Jeffrey Bluestone hands Sonoma CEO post to Stephen Dillynews2025-11-17T16:26:56+00:00November 17th, 2025|Endpoints News|
FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing studynews2025-11-14T20:48:04+00:00November 14th, 2025|Endpoints News|
EnGene posts more pivotal data for bladder cancer gene therapy, plans 2026 filingnews2025-11-11T12:30:20+00:00November 11th, 2025|Endpoints News|
#AHA25: CRISPR Therapeutics’ gene editing therapy halves cholesterol and triglycerides in early trialnews2025-11-10T15:25:01+00:00November 10th, 2025|Endpoints News|
Patient in Intellia CRISPR trial dies after being hospitalized with liver injurynews2025-11-07T02:34:55+00:00November 7th, 2025|Endpoints News|
Jennifer Doudna startup Azalea Therapeutics launches with $82Mnews2025-11-04T13:00:49+00:00November 4th, 2025|Endpoints News|
UniQure’s Huntington’s gene therapy is delayed, as FDA suggests it may walk back accelerated approval blessingnews2025-11-03T13:34:28+00:00November 3rd, 2025|Endpoints News|
